FeesSafety
Pluang+

5 reliable dividend stocks keep raising payouts yearly for steady passive income growth.

Market News
20 Nov 2026, 15:02 WIB
24/7 Wall Street
View Source
Bullish
5 reliable dividend stocks keep raising payouts yearly for steady passive income growth.

This article highlights five U.S.-listed companies—Johnson & Johnson, Procter & Gamble, Coca-Cola, Automatic Data Processing, and Lowe's—that have a strong track record of increasing dividends annually. These companies maintain dividend safety by paying out less than two-thirds of earnings and backing dividends with real cash flow, making them attractive for investors seeking reliable passive income. The article also explains how dividend reinvestment plans (DRIPs) and yield on cost strategies can help investors compound their income over time. Risks such as market valuation and sector-specific challenges are noted, but overall, these stocks offer a diversified, steady income stream suitable for long-term investors.

Highlighting companies known for steady dividend growth, Johnson & Johnson and Procter & Gamble remain actively traded on Pluang as of Nov 20, 2026, 20:02 WIB. Johnson & Johnson shares are priced at USD 269.68 with a 1-day gain of 0.95%, while Procter & Gamble trades at USD 169.81, up 1.17% for the day. Investors on Pluang show balanced interest in Johnson & Johnson with 52% buy orders, whereas Procter & Gamble sees heavier selling at 86%.

More News (JNJ)

TREMFYA shows significant improvement in spinal pain and inflammation in psoriatic arthritis patients in Phase 4 study

TREMFYA shows significant improvement in spinal pain and inflammation in psoriatic arthritis patients in Phase 4 study

Johnson & Johnson's TREMFYA (guselkumab) demonstrated significant improvements in spinal pain, stiffness, and MRI-confirmed inflammation in patients with axial psoriatic arthritis (PsA) in the Phase 4 STAR study. The study, the first of its kind usin...

Company Fundamentals
Bullish
14 minutes ago
Johnson & Johnson's new prostate cancer drug shows 75% response in early trials, boosting its strong pipeline.

Johnson & Johnson's new prostate cancer drug shows 75% response in early trials, boosting its strong pipeline.

Johnson & Johnson's investigational drug JNJ-6143, acquired through a $3.05 billion purchase of Halda Therapeutics, demonstrated a 75% overall response rate in a Phase 1 trial for metastatic castration-resistant prostate cancer. This promising early ...

Market News
Bullish
13 hours ago
Johnson & Johnson's new prostate cancer drug shows 75% response rate in early trial, boosting pipeline hopes.

Johnson & Johnson's new prostate cancer drug shows 75% response rate in early trial, boosting pipeline hopes.

Johnson & Johnson's investigational prostate cancer drug JNJ-6143 demonstrated a 75% overall response rate in a Phase 1 trial involving patients with advanced metastatic castration-resistant prostate cancer. This promising early result highlights the...

Market News
Bullish
18 hours ago
3 Dow Dividend Stocks with Long Histories Offer Reliable Retirement Income

3 Dow Dividend Stocks with Long Histories Offer Reliable Retirement Income

Coca-Cola, Johnson & Johnson, and JPMorgan Chase are highlighted as strong Dow dividend stocks ideal for retirement income due to their long track records and diverse business models. Johnson & Johnson leads with 64 consecutive years of dividend incr...

Market News
Bullish
21 hours ago
Invest in Coca-Cola, Johnson & Johnson, and JPMorgan for reliable retirement dividends from diverse sectors.

Invest in Coca-Cola, Johnson & Johnson, and JPMorgan for reliable retirement dividends from diverse sectors.

Coca-Cola, Johnson & Johnson, and JPMorgan Chase are highlighted as strong Dow Jones dividend stocks for reliable retirement income. Each company has a long history of dividend payments, with Johnson & Johnson boasting 64 consecutive years of increas...

Market News
Bullish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App